Filed under: Amgen Inc (AMGN), Options

Amgen (NASDAQ: AMGN) closed at $44.62 Tuesday.

On 3/13/08, the FDA Oncologic Drugs Advisory Committee (ODAC) is scheduled to review the use of Erythropoiesis stimulation agents, including Aranesp and JNJ’s Procrit, to treat chemotherapy induced anemia.

AMGN March option implied volatility is at 51; April is at 41; above its 26-week average of 33 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Permalink | Email this | Comments

Share This

This entry was posted on Wednesday, March 12th, 2008 at 1:47 pm and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.